ScholarIQanswers from OpenAlex & ORCID
Fred R. Hirsch
ResearcherPublications, citations & collaboration network
Fred R. Hirsch is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fred R. Hirsch have?
ScholarIQindexed works
Fred R. Hirsch has 763 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fred R. Hirsch have?
ScholarIQcitation count
Fred R. Hirsch has 52,799 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fred R. Hirsch?
ScholarIQh-index
Fred R. Hirsch has an h-index of 102 in OpenAlex.
What is the i10-index of Fred R. Hirsch?
ScholarIQi10-index
Fred R. Hirsch has an i10-index of 325 in OpenAlex.
What is the ORCID of Fred R. Hirsch?
ScholarIQorcid
The ORCID for Fred R. Hirsch is on the source record.
What is the OpenAlex record for Fred R. Hirsch?
ScholarIQopenalex
The OpenAlex for Fred R. Hirsch is on the source record.
What are the most-cited papers on Fred R. Hirsch?
ScholarIQmost cited works
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio V. Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James R. Jett, Montse Sánchez‐Céspedes, Jean‐Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio I. Wistuba, Pan‐Chyr Yang, Denise R. Aberle, Christian Brambilla, Douglas B. Flieder, Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah B. Doroshow, Sheena Bhalla, Mary Beth Beasley, Lynette M. Sholl, Keith M. Kerr, Sacha Gnjatic, Ignacio I. Wistuba, David L. Rimm, Ming‐Sound Tsao, Fred R. Hirsch
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric Bernicker, Carol Colasacco, Sanja Đačić, Fred R. Hirsch, Keith M. Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette M. Sholl, Robyn Temple‐Smolkin, Benjamin Solomon, Lesley Souter, Erik Thunnissen, Ming‐Sound Tsao, Christina B. Ventura, Murry W. Wynes, Yasushi Yatabe
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming‐Sound Tsao, Keith M. Kerr, Mark Kockx, Mary-Beth Beasley, Alain Borczuk, Johan Botling, Lukas Bubendorf, Lucian R. Chirieac, Gang Chen, Teh‐Ying Chou, Jin-Haeng Chung, Sanja Đačić, Sylvie Lantuéjoul, Mari Mino–Kenudson, André L. Moreira, Andrew G. Nicholson, Masayuki Noguchi, Giuseppe Pelosi, Claudia Poleri, Prudence A. Russell, Jennifer L. Sauter, Erik Thunnissen, Ignacio I. Wistuba, Hui Yu, Murry W. Wynes, Melania Pintilie, Yasushi Yatabe, Fred R. Hirsch